Dude, look at the market. Most of the offshore drillers hit 52-week lows today. The sell-off was not SDRL-specific.
National Energy Technology Laboratory issued the report. Using "NETL-TRS-3-2014" as a Google search term will return the report pdf as the first result.
A Duke University study (Avner Vengosh) found that faulty well completion, not hydraulic fracturing, was the cause of water pollution near oil and gas wells .
(Reuters) U.S. regional refining margins fell 6.66 percent on average in the week ended Sept. 12, declining in three out of the five regions, Credit Suisse said in a weekly report on Monday.
Margins in the Gulf Coast dipped the most, down 20.25 percent, while margins in the West Coast and Midwest fell 16.33 percent and 5.68 percent, respectively.
Rockies refining margins climbed 5.07 percent, and the margins in the Northeast rose 3.88 percent, Credit Suisse said.
The 6.66 percent average fall in U.S. refinery margins was calculated by taking the average of regional margins.
The following table shows the changes in refinery margins:
Date Northeast MidWest Gulf Coast Rockies West Coast
Current week 12-Sep-14 12.57 21.60 14.57 34.81 19.47
Previous week 05-Sep-14 12.11 22.90 18.27 33.13 23.27
Change 0.47 (1.30) (3.70) 1.68 (3.80)
Percent Change 3.88 (5.68) (20.25) 5.07 (16.33)
Trailing 4-week 12-Sep-14 11.56 20.50 17.38 32.97 20.76
Previous year 13-Sep-13 9.27 16.87 11.76 23.48 13.36
Change Y-on-Y 2.28 3.64 5.62 9.49 7.40
These transactions have nothing to do with retirement accounts. As Dr. Chan explained in his email reply, Kraus is selling stock acquired via option exercise in conjunction with estate planning. Option expiration dates and tax liability may vary based on whether Kraus is among the living or the dead.
His questions and comment may be partially valid.
Quoting Christian Steiner from the August 12 quarterly conference call transcript, "Our Distributor business also continues to grow, with strong re-order performance from Turkey and India, in particular. As mentioned, we are waiting for final product registration in Russia and the Middle East, which we hope to get soon, and we just signed on Taiwan. To date, we have not yet had meaningful sales from these countries."
Have you seen announcements within the past month that the product registrations in question have been approved and measurable sales have commenced?
Incentive stock options are eligible for favorable tax treatment in and of themselves and are not held in tax-deferred retirement accounts, which would automatically subject them to taxation as regular income upon withdrawal.
Missed the wider variety of perspectives in a public forum. I'll be hanging around but don't have any oversold stocks on my radar. Everything seems to be fairly valued to overbought. Will let you know when I see something.
That is untrue. Only one of the four NYSE MKT initial listing standards has a revenue requirement, and it states verbatim:
"Pre-tax income from continuing operations of at least $750,000 in its last fiscal year, or in two of its last three fiscal years." (NYSE MKT Company Guide, Part 1. Original Listing Requirements, Subsection 101.a.2)
Tecemotide may be on life support but not dead - yet. Still registering brain waves in colon, rectal and prostate cancer studies.
"Merck Serono will continue to supply tecemotide for ongoing investigator-sponsored trials in other indications in accordance with their agreements with the sponsors of these studies." (8-K, 12 Sep 14)
An early August news report indicated MPC and PSX were not interested in adding refineries. The same article article also quoted TSO as interested only in midcontinent assets but unaware of any for sale. VLO did not rule out adding capacity. CVR and PBF acknowledged interest, and Par was mentioned as a possible bidder. (CSP Daily News, "Who Might Buy CITGO Petroleum?")
Why did ENDP discontinue a Phase III clinical trial and return to BNC.TO global rights to the drug in 2012 if it holds blockbuster potential? The trial, designed to compare the drug with another drug not FDA-approved but widely-used off-label, was not recruiting at the expected rate and FDA issues with the trial design could not be resolved. It's a tough space littered with failed clinical trials, one dominated by an existing FDA-approved SOC with 70% success rate, and for which no new drugs have been approved for thirty years. CTSO shareholders beware.
Read booradley's comment posted ahead of yours. He speaks the truth. Zack's just spams for clicks to charge for advertising.
Checking message board history (which I don't encourage - yawn!!), you probably would find a dozen or more people who, over the years, said getting to $1+ would be easy. Don't recall if I just thought it would be easy or publicly expressed the thought and can be counted among those who were very wrong.
Eliminating a material interest in the company may meet one prerequisite, but Kraus would not be able to meet the timeframe requirement to qualify as independent, even if he resigned as Chairman of the Board today.